Pestana Roberto Carmagnani, Hassan Manal M, Abdel-Wahab Reham, Abugabal Yehia I, Girard Lauren M, Li Donghui, Chang Ping, Raghav Kanwal, Morris Jeff, Wolff Robert A, Rashid Asif, Amin Hesham M, Kaseb Ahmed
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncotarget. 2018 Dec 28;9(102):37721-37732. doi: 10.18632/oncotarget.26507.
Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) play critical roles in angiogenesis in hepatocellular carcinoma (HCC). In addition, recent data suggest that Ang-1/Ang-2 are involved in regulating the immune response. The aim of our study was to explore the clinical prognostic significance of plasma Ang-1 and Ang-2 in HCC. We prospectively enrolled and collected data and blood samples from 767 HCC patients treated at MD Anderson Cancer Center between 2001 and 2014. Controls consisted of cirrhotic patients ( = 75) and healthy volunteers ( = 200). The cutoff value was the median level of each angiogenic factor. Overall survival (OS) was estimated by Kaplan-Meier curves and compared by the log-rank test. Higher plasma Ang-2 was significantly associated with advanced clinicopathologic features of advanced HCC and lower OS. Median OS was 61.8 months (95% confidence interval [CI], 45.1-78.5 months) for low Ang-2 compared with 28.5 months (95% CI, 24.8-32.1 months) for high Ang-2 ( < 0.001). In contrast, higher Ang-1 was associated with longer OS. Median OS was 37.2 months (95% CI, 31.0-43.4 months) for high Ang-1 compared with 26.2 months (95% CI, 22.2-30.3 months) for those with low Ang-1 (p = 0.043). In conclusion, our findings indicate that plasma Ang-1 and Ang-2 levels are potential diagnostic and prognostic biomarkers in HCC.
血管生成素-1（Ang-1）和血管生成素-2（Ang-2）在肝细胞癌（HCC）的血管生成中起关键作用。此外，最近的数据表明，Ang-1/Ang-2参与调节免疫反应。我们研究的目的是探讨血浆Ang-1和Ang-2在HCC中的临床预后意义。我们前瞻性地招募并收集了2001年至2014年在MD安德森癌症中心接受治疗的767例HCC患者的数据和血液样本。对照组包括肝硬化患者（n = 75）和健康志愿者（n = 200）。临界值为每种血管生成因子的中位数水平。总生存期（OS）通过Kaplan-Meier曲线估计，并通过对数秩检验进行比较。较高的血浆Ang-2与晚期HCC的晚期临床病理特征和较低的OS显著相关。低Ang-2组的中位OS为61.8个月（95%置信区间[CI]，45.1 - 78.5个月），而高Ang-2组为28.5个月（95%CI，24.8 - 32.1个月）（P < 0.001）。相反，较高的Ang-1与较长的OS相关。高Ang-1组的中位OS为37.2个月（95%CI，31.0 - 43.4个月），而低Ang-1组为26.2个月（95%CI，22.2 - 30.3个月）（P = 0.043）。总之，我们的研究结果表明，血浆Ang-1和Ang-2水平是HCC潜在的诊断和预后生物标志物。
